New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareMGF (Mechano Growth Factor) vs Ovagen

MGF (Mechano Growth Factor) vs Ovagen

Side-by-side comparison of key properties, dosing, and research.

Anabolic & IGF
MGF (Mechano Growth Factor)
Anti-Aging & Longevity
Ovagen
Summary
MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is locally produced in muscle tissue in response to mechanical damage from exercise. It activates muscle satellite cells (stem cells) to proliferate and repair damaged fibers, making it specifically targeted at exercise-induced hypertrophy.
Ovagen is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, primarily targeting liver tissue. It supports hepatocyte function, liver cell regeneration, and protection against hepatic aging and disease. Ovagen is used in protocols for chronic liver disease, hepatoprotection, and metabolic liver conditions including fatty liver disease.
Half-Life
Native MGF: minutes. PEG-MGF: ~3 days
Short (minutes); sustained gene-regulatory effects
Admin Route
SubQ, IM
SubQ, Oral
Research
Typical Dose
200–400 mcg
10 mg per day
Frequency
1–2 times per week
Daily for 10–30 days
Key Benefits
  • Activates muscle satellite cells for repair and growth
  • Accelerates recovery from muscle damage
  • Synergistic with IGF-1 LR3 (different mechanisms)
  • Promotes muscle hypertrophy specifically at exercised muscles
  • Faster recovery between training sessions
  • Potential for injury repair in connective tissue
  • Hepatoprotective effects against toxic, viral, and metabolic liver damage
  • Promotes hepatocyte regeneration and liver tissue repair
  • May reduce liver fibrosis progression
  • Supports liver metabolic function and detoxification capacity
  • Anti-aging effects on hepatic tissue
  • Useful in NAFLD/MASH supportive protocols
  • Compatible with NAD+, glutathione, and BPC-157 in liver health stacks
Side Effects
  • Muscle soreness (satellite cell activation)
  • Injection site irritation
  • Hypoglycemia risk (modest, less than IGF-1 LR3)
  • Generally well tolerated
  • Mild injection site reactions
  • No clinically significant hepatotoxicity reported
Stacks With